Bristol Myers Squibb is executing a visible portfolio transition, with its Growth Portfolio now surpassing Legacy Portfolio.
If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...
Das erste Halbjahr 2026 brachte 4,66 Mrd. Euro Umsatz. Die DSM-Firmenich-Aktie kostet am 16.10.2026 107,93 Euro, 1,72 Prozent ...
Die Aktienkurse in Europa sind am Freitag uneinheitlich in den Handel gestartet. Die Stimmung an den Märkten war jedoch ...
La società tecnologica LG CNS si è aggiudicata un progetto di modernizzazione del sistema bancario centrale delle cooperative ...
Tartana unveils high-grade copper-gold targets at OK-Bellevue in Queensland as Haranga delivers high-grade gold in California ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results